DexCom, Inc. - DXCM STOCK NEWS

Dexcom has announced that its G6 Continuous Glucose Monitoring (CGM) System will now be available to individuals of all ages with type 1 and type 2 diabetes in Manitoba. This update, effective from March 14, 2023, allows eligible patients to access the device without needing preapproval, enhancing accessibility and reducing the administrative burden on healthcare providers. By expanding access to real-time glucose monitoring, Manitoba positions itself as a leader in Canada, promoting better diabetes self-management and potentially lowering emergency care needs related to severe hypoglycemia.

DexCom, Inc. (NASDAQ: DXCM) reassures stakeholders amid speculation regarding its relationship with Silicon Valley Bank (SVB) following recent developments. The company clarifies it has no material exposure to SVB, holding about $2.5 billion in cash and short-term marketable securities, of which only $2.7 million is at SVB. DexCom emphasizes its diversified banking relationships, ensuring that it is not reliant on SVB. This communication aims to maintain investor confidence and highlight the company's robust financial position.

DexCom, Inc. (NASDAQ:DXCM) announced its participation in two upcoming investor conferences. Sean Christensen, Vice President of Finance and Investor Relations, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 2:45 PM EST. Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present at the Raymond James 44th Annual Institutional Investors Conference on March 7, 2023, at 3:25 PM EST. Webcast links will be available on the Dexcom Investor Relations website and archived for future access.

Dexcom, Inc. (NASDAQ: DXCM) is set to showcase its continuous glucose monitoring (CGM) portfolio at the 16th International Conference on Advanced Technologies and Treatments for Diabetes in Berlin from February 22-25, 2023. The company reports the successful launch of Dexcom G7 in eight countries and highlights the growing significance of Dexcom ONE in expanding CGM access, impacting over 3.5 million lives globally. Initial feedback on Dexcom G7 indicates high user satisfaction with its features, including a 60% smaller design and a market-leading warmup time of 30 minutes. Dexcom G6 continues to excel in connectivity, facilitating integration with various insulin delivery systems.

The U.S. Centers for Medicare & Medicaid Services has approved coverage for the Dexcom G7, a continuous glucose monitoring system designed for diabetes management. Launching on February 17, 2023, the G7 is touted as the most accurate CGM, eliminating routine fingersticks and offering real-time glucose readings. This approval cements Dexcom's position as a leading CGM provider, making the G7 accessible to Medicare patients. The device features a 30-minute sensor warm-up, smaller design, and improved app integration, enhancing user experience and diabetes management.

DexCom reported its Q4 and full year 2022 results, highlighting a 17% revenue increase to $815.2 million in Q4 and 19% growth for the year, totaling $2.91 billion. U.S. revenue grew by 17% and international by 15% (27% organic). GAAP operating income rose to $125.4 million (15.4% margin), while non-GAAP reached $172.1 million (21.1% margin). The company launched the Dexcom G7 CGM system and plans for a revenue guidance of $3.35 - 3.49 billion for 2023, signifying 15-20% growth. DexCom ended 2022 with $2.46 billion in cash and equivalents.

Dexcom, Inc. (NASDAQ:DXCM) has launched the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System, announced through a new Super Bowl commercial featuring Nick Jonas. The G7 promises to be the most accurate and user-friendly CGM on the market, helping diabetes patients improve their health management without fingersticks. The campaign aims to raise awareness among the 4.8 million insulin-dependent Americans, highlighting how the G7 can lower A1C levels and enhance time in range. Approximately 3.3 million viewers who currently do not use CGM have coverage options, making awareness crucial for better diabetes management.

Mednow Inc. (OTCQX: MDNWF) has launched an enhanced Virtual Diabetes Management program that integrates Dexcom G6 real-time continuous glucose monitoring (rtCGM) supplies and diabetes support services. This program offers convenient home delivery and access to certified diabetes educators and clinical pharmacists for personalized care. Initially available in Ontario and British Columbia from early February, the integration aims to improve accessibility and management for diabetes patients. The partnership with Dexcom aims to leverage their technology to enhance patient care and support effective diabetes management.

DexCom, Inc. (NASDAQ:DXCM) announced its plans to release financial results for the fourth quarter and full year 2022 on February 9, 2023, post market close. The management will discuss the results in a conference call at 4:30 p.m. ET on the same day, which will also be available via webcast. This financial report is crucial for investors and stakeholders to gauge the company's performance in the diabetes care technology sector.